Adenosine deaminase binding protein (AdAbp), a glycoprotein found in the epithelial cells of the brush border of the proximal tubule, is shed into urine following kidney damage. A sandwich enzyme immunoassay is described that uses two monoclonal antibodies, URO-4 (S27) and URO-4a (S23), which react with different epitopes on AdAbp (2, 24). Release of AdAbp into the urine appears to reflect the severity of the insult to the nephron and its measurement may assist in distinguishing between tubular disease and glomerular disease and may be useful in indicating renal toxicity.
INTRODUCTION
Adenosine deaminase (AdA, EC 3.5.4.4) is present in most mammalian tissues and catalyzes the hydrolysis of adenosine to inosine with the release of ammonia. Its role in purine metabolism appears essential for lymphocyte maturation and differentiation, since a deficiency in AdA results in severe combined immunodeficiency disease (8, 1 1).
Multiple forms of AdA have been reported based on charge and size heterogeneity (1, 7, 18). The differences in apparent molecular weight have been attributed to the ability of AdA to bind to a complexing or binding protein found in many tissues including colon, lung, spleen, placenta, liver, and kidney (1 2, 15, 17, 22, 23, 25] . Previous studies have demonstrated that the stoichiometric ratios of AdA to binding protein vary in different tissues; the liver and spleen, for example, have more AdA than binding protein while the lung and kidney have an excess of binding protein (1 5).
Both a soluble and membrane form of AdA binding protein (AdAbp) have been observed in the kidney (15, 17, 18) . Recent experiments have demonstrated AdAbp to be an integral membrane protein (3), which suggests that the soluble form originates from a membrane bound precursor.
Using monoclonal antibodies, AdAbp has been detected by immunofluorescence in the epithelial cells of the proximal tubules ofthe kidney, with faint staining also observed in the epithelial cells of Bowman's capsule as well as the loop of Henle (5). These recent studies have extended earlier reports on the localization of AdAbp in the kidney (15, 16).
Low levels of AdAbp have been detected in the plasma and urine of normal individuals by immunoassay (1 7). Since other investigators have demonstrated the release of kidney-specific antigens into the urine of individuals with various renal diseases (14,28), we postulated that elevated levels ofAdAbp may also appear in the urine following insults to the nephron. This paper extends our previous findings (19) , which demonstrated increased levels of AdAbp in the urine of patients with various renal diseases.
METHODS

Pafienfs.
Normal controls were healthy laboratory personnel under the age of 40 who had normal BUN and creatinine levels, and no history of past renal disease. The patients classified in this study as having glomerular disease had had renal biopsies demonstrating such lesions, with no other renal pathology evident in the biopsy specimen, in the same week that their urines were assayed for AdAbp. Patients classified as having acute tubular necrosis had undergone an acute episode of hypotension, followed by oliguric renal failure 1 7 2 hours before AdAbp was measured. Patients with contrast dye or aminoglycoside-induced renal failure had a doubling of the baseline serum creatinine following administration of the contrast media or the aminoglycoside. Patients classified as having cyclosporine toxicity were renal or liver allograph recipients whose elevated creatinine levels fell 20.4 mg/dl within 72 hours of decreasing the dose ofcyclosporine.
Vol. 14, NO. 2, 1986 AdA BINDING PROTEIN 233 4a (S23), murine monoclonal antibodies (Cambridge Research Laboratory, Cambridge, MA) were formatted into a sandwich enzyme immunoassay as previously described (19) . Briefly, the two antibodies were purified from ascites fluid by ion exchange chromatography using previously described techniques (10) . URO-4a was conjugated to horseradish peroxidase (HRP, EC 1.1 1.1.7) by the method of Wilson and Nakane (27) and appropriate titers determined. URO-4 was passively adsorbed onto the surfaces of Immulon 2 microtiter plates (Dynatech Laboratories, Inc., Alexandria, VA) from a 10 mg/L solution of antibody in a Na,CO,/NaHCO, buffer, 50 mmoVL, pH 9.6. The plates were washed with phosphate-buffered saline solution containing Tween 20 polyoxyethylene sorbitan monolaurate (0.5 m a ) . AdAbp was partially purified from the urine of patients with kidney disease by salting out with (NH,),SO, followed by lectin affinity chromatography using Con A sepharose (Pharmacia, Piscataway, NJ). This material was diluted in bovine serum albumin and used as a standard in the assay described below. Uririe Samples. Untimed urine specimens were collecteb from normal individuals and from patients being treated at the Massachusetts General Hospital for renal diseases. The specimens had preservatives added to give the following final concentrations: Tris 20 mmol/L, benzamidine 1 mmoVL, and EDTA 10 mmoVL. The pH of the specimens then ranged from 6.0 to 7.5. The urines were stored at 4°C overnight prior to removing cell debris and insoluble material by centrifugation (1,500 x g. 10 min), and then stored at 4°C until assayed.
Assay Protocol. Duplicate 1 00-p1 portions of patients' urines, assay controls, and known assay standards are added to previously prepared URO-4coated microtiter plates, and incubated for 1 hour at 25°C. The plates are washed three times with the Tween-containing phosphate-buffered saline to remove nonbound antigen and other materials. URO-4a-HRP (1.3 mg/L) is added to each well and incubated for 1 hour at 25°C. The unbound conjugate is removed by aspiration and the plates are washed three more times with Tween-containing phosphate-buffered saline. Add 100 p1 of the chromogen solution, which contains, per liter, 2 g of o-phenylenediamine and 500 pl of 30% voVvol H,O, in citrate (1 9 mmol/L)-phosphate (62 mmol/L) buffer, pH 5.0. After 1 hour at 25"C, the enzymatic action is stopped by adding 100 p1 of 4.5 moVL sulfuric acid. The enzymatic activity is quantified by measuring, at 490 nm, the absorbance of the color that has developed.
AdAbp levels in patients' urines are determined by comparison with the standard curve. The stan-dard curve is based on arbitrary units of reactivity, and defined as the amount of AdAbp present in 100 p1 of sample that increases the absorbance at 490 nm by one absorbance unit (1.000 A ) in the above assay.
Stability of AdAbp in Urine.
To assess the stability of AdAbp to pH extremes, we added increasing volumes of HCl or NaOH (1.0 mol/L) to different aliquots of four patients' urines in order to generate a pH range of 4 to 8. We incubated the urine specimens at 37°C for 3 hours, then added the corresponding acid or base to neutralize the specimens before the assay. We corrected AdAbp concentrations for changes in volume due to the addition of acid or base.
In another experiment, designed to assess the stability of AdAbp to freezing, urines from 50 patients were frozen overnight at -7O"C, assayed, and the results were compared with those for samples kept at 4°C.
Saniple Collectiori Tittle. To assess the effect of sampling time on AdAbp content, we collected 24hour urine specimens from three patients and assayed each voiding separately. Using a modification of the Jaffe method (9), we also determined the concentration of creatinine in these samples.
RESULTS
Staridard C w w . The standard curve is expressed in arbitrary units of AdAbp at this time until a homogeneous preparation can be obtained for standardization. In our hands, the standard curve (Fig.  1) is linear from zero up to 1.5 units. Above this point, nonlinearity results due to the saturation of antigen binding sites.
Reproducibility. We ran pooled urine specimens from patients with elevated levels ofAdAbp 10 times Low control 0.426 0.026 6.2
In arbitrary units.
1 to assess within-run variation and another pool of urine specimens from patients 18 times to assess between-run variation. The resulting coeficients of variation were less than 10% (Table I) . Sensitivity. Assay sensitivity was defined as that concentration of AdAbp corresponding to two standard deviations (2 SDs) from the mean absorbance of the zero standard run 10 times. This assay is capable of detecting 0.07 units of AdAbp.
Aiialytical Recowry. AdAbp was added to 32 individual normal urines in order to determine recovery levels. The recovery in these urines ranged from 77.1 to 115.9% (mean 96.9% f 9.4). In six of these urines the recovery ranged from 77.1 to 89.2% (mean 82.3% f 5.8) suggesting a possible interference in the urine of these individuals. AdAbp concentrations in urine samples stored frozen overnight at -70°C were the same as in samples of the same urine stored at 4°C (Student's t-test, p > 0.05). To assess the long-term stability ofAdAbp at 4"C, we re-assayed 25 urine samples from patients after 4 months storage. Recoveries ranged from 75 to 91% (Student's t-test, p 2 0.01).
Stability of AdAbp in
Eflect of Sanipling Time. AdAbp concentrations
in the urine specimens collected during 24 hours are shown in Fig. 3 . For the values averaged for the 24 hours, the CV for samples from an individual ranged from 8 to 20940, exceeding the fluctuation seen in the precision studies summarized in Table I . We attributed this variation to changes in urine flow and tried to normalize this data using the urinary creatinine concentration. This approach did not, however, sig- 
Clinical Stitdies. Measurements of AdAbp levels
for the normal controls and for the five groups of patients with clinically well-defined renal disease are summarized in Table 11 . In normal urine samples, AdAbp concentrations averaged 0.06 arb units. For urine samples from the 29 patients with biopsyproven glomerular disease, AdAbp concentrations ranged from 0.08 to 0.18. In 1 1 patients with glomerular disease accompanied by varying degrees of tubulointerstitial inflammation, AdAbp values were higher, ranging from 0.20 to 0.60. In the urine of patients with acute tubular necrosis induced by hypotension or contrast dye administration, AdAbp concentrations ranged from 0.30 to greater than 2.0. AdAbp levels ranged from 0.60 to greater than 2.0 in patients developing toxicity due to aminoglycoside or cyclosporin A administration. Following the initial insult to the nephron or upon withdrawal of the nephrotoxic drug, AdAbp levels declined.
DISCUSSION
The diagnosis of renal disease currently depends upon observed changes in urine output, increases in the serum concentrations of urea nitrogen and creatinine, and abnormalities detected upon urinalysis. These measurements do not indicate the anatomical site of damage, nor do they adequately define the extent or reversibility of the disease process. Thus renal biopsies must be performed frequently. With the development of monoclonal antibodies specific for different anatomical sites in the kidney, the potential exists for the development of new immunoassays that may improve upon current diagnostic tests.
We have taken this approach in the development of an immunoassay for AdAbp, a well-described proximal tubule glycoprotein. This immunoassay demonstrates that very low levels of AdAbp are released into the urine of normal individuals, in contrast to the urine of patients with tubular damage, where significant elevated levels ofAdAbp were observed. Patients with glomerular disease were found to have higher than normal levels but could be differentiated from patients with tubular damage in most cases. The elevation observed with glomerular disease may be explained by the presence of low amounts of AdAbp in Bowman's capsule which may be shed with disease, by tubulointerstitial inflammation which may accompany glomerular disease, or by the loss of plasma AdAbp accompanying proteinuria.
In patients with well-defined nephrotoxicity due to the administration of either gentamicin or cyclosporin A, AdAbp levels were significantly in- creased. Although informative, AdAbp levels in urine may not be useful in providing an early warning of gentamicin toxicity since increased levels have been observed in patients without a concurrent rise in serum creatinine (Fig. 4) . On the other hand, changes in AdAbp levels appear promising in following those patients who are receiving immunosuppressants such as cyclosporin A. In these patients, decreasing the dose ofcyclosporin A will result in a fall of AdAbp levels within 36 hours, frequently before a fall in serum creatinine has occurred (21) . Previously proposed markers of renal damage, such as B,-microglobulin, are unstable if the pH of the sample is below 6.0 (4,6, 13). AdAbp was found to be stable from pH 5.0 to 8.0. At pH 4, AdAbp loses approximately 75% of its reactivity within 3 hours. The stability at pH 5.0 is advantageous and suggests that AdAbp is a superior marker to p2microglobulin for measuring kidney damage.
The ability to obtain diagnostically useful information from an untimed urine specimen is desirable due to the difficulty and inconvenience in collecting accurate 24-hour urine specimens or first morning void specimens. AdAbp concentrations varied during a 24-hour collection period for the three patients studied (Fig. 3) . The variation between sampling times exceeded the limits of precision of this assay for two of the three patients. Expressing AdAbp levels as a function of urinary creatinine concentration did not significantly reduce this variation, even though a similar approach is used for expressing urine levels of N-acetyl-8-D-glucosaminidase (26) . We found that the use of a single untimed urine specimen instead of a 24-hour specimen introduced an additional 16% uncertainty in AdAbp measure-236 THOMPSON, PIPER, A N D KIDD TOXICOLOGIC PATHOLOGY ments in some cases. Given the degree of separation between the level of AdAbp observed in urine specimens of patients with and without active acute tubular disease (Table 11 ), this variation was considered acceptable.
We also evaluated possible storage conditions for urine samples. AdAbp was found to be stable to one freeze-thaw cycle at -70°C. Storage at 4°C is more convenient and our study demonstrated that AdAbp could be stored for four months with recoveries ranging from 75 t o 91%.
The measurement of AdAbp, like that of other brush border proteins, is a non-specific measurement ofinjury. Various events, such as acute tubular necrosis, cyclosporin A and gentamicin toxicity, and acute cellular rejection (20, 21) all result in the release of AdAbp into the urine and are thus indistinguishable. Despite this shortcoming, useful clinical information can be obtained by correlating assay results with the clinical situation and by serial performance of the assay (21) . With the development of other assays to new markers recognized by other monoclonal antibodies, better discrimination between the various forms of injury may be possible.
